Latest News and Press Releases

Hamilton, March 07, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a...

Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have...

Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular mRNA significantly increasing protein expression...

HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:...

Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the...

Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process  Supports Bentrio growth strategy together with strategic contract...

Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...

Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...

Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...

Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...